abstract |
The present invention relates to muscarinic receptor regulation using 3- [4- (butylthio) -1,2,5-thiadiazol-3-yl] -1-azabicyclo [2.2.2] octane transdermal formulation. It provides a method for treating an associated disease. The present invention provides 3- [4- (butylthio) -1,2,5-thiadiazol-3-yl] -1-azabicyclo [2.2.2] octane patch formulations for desired transdermal administration. |